Drug Trial Radar · NCT00979901
Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)
Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,577
Actual
Start
Mar 2000
Primary completion
May 2000
Study completion May 2000
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the ability of montelukast to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine and placebo.
Conditions
- Seasonal Allergic Rhinitis
Interventions
Comparator: montelukastDrug
10 mg montelukast tablet given once daily at bedtime for 2 weeks
Comparator: loratadineDrug
10 mg loratadine tablet given once daily at bedtime for 2 weeks
Comparator: placeboDrug
placebo tablet given once daily at bedtime for 2 weeks
Comparator: montelukast/loratadineDrug
montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Daytime Nasal Symptoms Score Over 2 WeeksTime frame: Baseline and Week 2
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.